Reduced immunogenicity of MYC amplified, metastatic prostate cancer.
1/5 보강
[OBJECTIVES] Through a genomics-based approach analyzing gene expression levels and adaptive immune receptor recombinations, we sought to determine whether MYC amplification was associated with a wors
APA
Kahlon S, Barker VR, et al. (2026). Reduced immunogenicity of MYC amplified, metastatic prostate cancer.. Oncoscience, 13, 35-43. https://doi.org/10.18632/oncoscience.644
MLA
Kahlon S, et al.. "Reduced immunogenicity of MYC amplified, metastatic prostate cancer.." Oncoscience, vol. 13, 2026, pp. 35-43.
PMID
41743583 ↗
Abstract 한글 요약
[OBJECTIVES] Through a genomics-based approach analyzing gene expression levels and adaptive immune receptor recombinations, we sought to determine whether MYC amplification was associated with a worse outcome and reduced immunogenicity.
[METHODS] MYC copy numbers and the presence of adaptive immune receptor (IR) recombination sequencing reads were quantified in genomics files representing prostate cancer samples.
[RESULTS] Our results showed that increased MYC amplification was found in metastatic stages of prostate cancer. Furthermore, increased MYC amplification was not only associated with worse progression-free survival but also with reduced immunogenicity in metastatic tumors, as determined by the recovery of a reduced numbers of adaptive IR recombination sequencing reads from tumor RNAseq and tumor whole genome sequence files.
[CONCLUSIONS] MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics files.
[METHODS] MYC copy numbers and the presence of adaptive immune receptor (IR) recombination sequencing reads were quantified in genomics files representing prostate cancer samples.
[RESULTS] Our results showed that increased MYC amplification was found in metastatic stages of prostate cancer. Furthermore, increased MYC amplification was not only associated with worse progression-free survival but also with reduced immunogenicity in metastatic tumors, as determined by the recovery of a reduced numbers of adaptive IR recombination sequencing reads from tumor RNAseq and tumor whole genome sequence files.
[CONCLUSIONS] MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics files.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- MYC amplification is common in cancer of the stomach and gastroesophageal junction, correlates with male sex and reduced response to neoadjuvant therapy.
- Small B-cell lymphoma highly suspicious for splenic marginal zone lymphoma with L265P mutation and copy-number gain presenting as severe autoimmune hemolytic anemia: a case report with literature review.